Why Immunome (IMNM) Stock News & Analysis

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology ETF was off 0.9%. IMNM opened at $20.83 and touched $19.36, with about 1.6 million shares changing hands by 3:54 p.m. EST, according to market data.

5 January 2026

NASDAQ:IMNM·Stock Market

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome, Inc. is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a biotech stock in opposite directions at the same time. On the one hand: a clear late-stage efficacy win that supports an FDA filing. On the other: a proposed $400 million common stock offering that introduces near-term dilution risk. Reuters+2Immunome Investors+2

16 December 2025

Biotechnology·NASDAQ:IMNM·Stock Market

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree.

15 December 2025

NASDAQ:IMNM